



BRAINWARE PHARMA CHRONICLES

e-ISSN No. 3049-2831



Contents:

Student Artwork / From the Desk of Editor-in-Chief / From the Desk of Honorable Vice Chancellor / Departmental Events & Activities / Departmental Achievements / Faculty Achievements / Student Achievements / Departmental Best Practices / MoU Highlights / Faculty Insights & Scholarly Reflection / Herbal Garden Distinctive Activities / Drug Information Bulletin / Banned Antibiotics/Spurious Drugs/Convocation 2025 / Significant Milestones Achieved by Brainware University 2025 / Student Artwork

Published by the Department of Pharmaceutical Technology, Brainware University



Scan to read [Brainware Pharma Chronicles](#)

© 2025 Brainware University, Department of Pharmaceutical Technology. All rights reserved. No part of this publication may be reproduced or transmitted without prior written permission.



Editorial Board Members



Chief Editor

Dr. Prasenjit Mondal

Professor & HOD. Department of Pharmaceutical Technology

Email: hod.pt@brainwareuniversity.ac.in



Associate Editor

Ms. Arpita Biswas

Associate Professor, Department of Pharmaceutical Technology

Email: arb.pt@brainwareuniversity.ac.in



Associate Editor

Ms. Subarna Mahanti

Assistant Professor, Department of Pharmaceutical Technology

Email: sum.pt@brainwareuniversity.ac.in



Associate Editor

Mr. Bramhajit Chatterjee

Assistant Professor, Department of Pharmaceutical Technology

Email: bc.pt@brainwareuniversity.ac.in



Guest Editor

Dr. Sumanta Mondal

Associate Professor and NSS Programme Officer (Unit-IX); SCHOOL OF PHARMACY; GITAM (Deemed to be University)

Email: msumanta@gitam.edu



Guest Editor

Prof. Madya Dr. Malina Jasamai

Deputy Director (Quality Management System) Centre for Quality Assurance (Kualiti UKM) Universiti Kebangsaan Malaysia

Email: malina@ukm.edu.my

Publishing Committee Members



Dr. Prasenjit Mondal
*Professor & HOD, Department of Pharmaceutical
Technology, Brainware University)*



Ms. Bandana Basu
*(Librarian, Central Library,
Brainware University)*



Biplab Kumar Chandra
*(Librarian, Department of Pharmaceutical
Technology, Brainware University)*



Kaushik Das
*(Library Assistant, Department of Pharmaceutical
Technology, Brainware University)*



CONTENTS

Chapter Names	Page No.
Student Artwork	01
From the desk of Editor-in-Chief	02
From the desk of Honorable Vice Chancellor	03
Departmental Events & Activities	04-12
Departmental Achievements	13-15
Faculty Achievements	15-17
Student Achievements	18-19
Departmental Best Practices	19-24
MoU Highlights	25
Faculty Insights & Scholarly Reflection	26-29
Herbal Garden Distinctive Activities	30
Drug Information Bulletin	31
List of Banned Antibiotics	32-33
List of Spurious drugs	34
Convocation 2025	35
Significant Milestones Achieved by Brainware University 2025	36-37
Student Artwork	38



Student's Artwork



Artwork by- *Sanjana Singha, BPharm, 2nd Year*

From the desk of Editor-in-Chief



Prof. Dr. Prasenjit Mondal

It gives me immense pleasure to present **Volume 1, Issue 2 (January 2025 – July 2025)** of *Brainware Pharma Chronicles*, the official newsletter of the Department of Pharmaceutical Technology, Brainware University. We are also delighted to announce that the newsletter has been assigned an **e-ISSN: 3049-2831**, marking a significant milestone in its academic and professional recognition. This issue is made even more enriching with the introduction of the activities of our **Drug Information Centre (DIC)**, recognized by the **Indian Pharmaceutical Association (IPA)**. We are also launching the **DIC Bulletin**, aimed at providing up-to-date, evidence-based drug information that will be of great value to our readers. We hope this issue continues to inspire, inform, and reflect the academic and professional growth of our department.

Warm regards,
Prof (Dr). Prasenjit Mondal
Head of Department. Pharmaceutical Technology

From the desk of Hon. Vice Chancellor



Prof. Sankar Gangopadhyay

It is my pleasure to announce the publication of the second issue of the Newsletter series by the Department of Pharmaceutical Technology. The Newsletter will showcase the Department's commitment to research, academic activities and societal impact as well for the period extending from January to July 31 in the year 2025. Further, the Newsletter will provide the ideal platform for knowledge sharing among the faculty members, research scholars and students in the field of research, academics and community engagement. I congratulate the members of the editorial board and other concerned stakeholders in this context. Finally, I wish that the Newsletter leads to the enhancement of research, academic and societal activities.

Sankar Gangopadhyay

Warm regards,
Prof. Sankar Gangopadhyay
Vice Chancellor, Brainware University

Departmental Events & Activities

21.01.25 and 22.01.25 – Designing the Future of Pharmaceuticals: Hands-on Workshop on CADD



From January 21st to January 22nd, 2025, the Department of Pharmaceutical Technology conducted a two-day workshop on **CADD and QSAR**, exploring advanced computational tools in drug discovery. The sessions emphasized the integration of **Indian traditional medicine with modern techniques**, offering participants practical insights into accelerating drug development through innovative approaches.

24.01.25 – *Empowering Educators: Faculty Development Programme on Innovative Teaching and Research in Pharma Sciences*



From January 24th to January 31st, 2025, the Department of Pharmaceutical Technology hosted a week-long Faculty Development Programme, focusing on the **integration of synthetic drugs and Indian medicinal plants** for sustainable therapeutics. The sessions explored **recent advancements** and encouraged a **holistic approach** to drug development by bridging modern science with traditional knowledge.

06.03.25 – *Pharma Anveshan 2025: A Confluence of Ideas, Innovation, and Young Researchers*



On March 6th 2025, the Department of Pharmaceutical Technology organised National Pharmacy Education Day to celebrate the birthday of Prof. M. L. Shroff, the Father of Pharmacy.

18.03.25 – *Voices for Equality: Workshop on Gender Sensitization and Women Empowerment*



On March 18th, 2025 the **Department of Pharmaceutical Technology** conducted an awareness programme to highlight **gender equality and women empowerment**. **Interactive quizzes and discussions** helped students understand gender bias and inclusivity, fostering a sense of responsibility towards promoting equality in society.

22.03.25 – *Bridging the Gap: Industry Visit to Imethia Biosolutions for Real-World Pharmaceutical Insight*



On March 22nd 2025, the Department of Pharmaceutical Technology organized an industrial visit to ImTheia Biosolutions for BA/BE Study Exposure. Students gained firsthand experience with BA/BE study protocols, observed demonstrations of HPLC and LC-MS/MS systems, and learned about sample preparation, data analysis, and regulatory practices in bioanalytical research.

03.04.25 – *From Campus to Career: Industry Interface Programme with Pharma Experts*




On April 4th, 2025, the Department of Pharmaceutical Technology organized an **Industry Interface Programme**, connecting students with **leading pharma professionals**. The session provided insights into **current industry trends**, career pathways, and real-world challenges, preparing students for a seamless transition into the pharmaceutical sector.

17.04.25 – Outreach Activity: Awareness camp on DIC, Brainware University's Drive Towards Rational Drug Use and Patient Empowerment



On 17th April, 2025, the Department of Pharmaceutical Technology organized an **Awareness Camp on Drug Information Centre (DIC)** to promote rational drug use. The initiative aimed to educate the public on safe medication practices, reinforcing Brainware University's commitment to patient empowerment and responsible healthcare.

24.04.25 – Protecting Innovation: Seminar on Intellectual Property Rights in Pharmaceutical Research



On 24th April 2025, the Department of Pharmaceutical Technology organized a seminar on *Intellectual Property Rights in Pharmaceutical Research*.

28.05.25 – A Fond Adieu: Farewell Ceremony Celebrating the Journey of Outgoing Graduates



On May 28th 2025, the Department of Pharmaceutical Technology organized a “Farewell” ceremony for the final year students of DPharm, BPharm, and MPharm.

21.06.25 – Wellness in Motion: Celebrating International Yoga Day for Holistic Health




On June 21st 2025, the Department of Pharmaceutical Technology celebrated “International Yoga Day,” where both students and teachers participated.

09.07.25 – *Knowledge for Service: DIC Training Empowers NSS Volunteers on Rational Drug Use*



On July 9th 2025, the Drug Information Centre, Department of Pharmaceutical Technology, conducted a training session for NSS volunteers on the safe and rational use of medicines.

In the Words of Our Faculty: Exploring Ideas Beyond the Classroom



Department of Pharmaceutical Technology, published a book titled “Synergies in Healing- The Convergence of Modern Pharmaceutical Science and Traditional Practices” with ISBN:9788196351465

Departmental Achievements

Paper Publication Records

**Total Departmental Publications from
January 2025 to June 2025: 58**

**Teacher-Student Publication Impact Factor
(I.F. JCR. Clarivate) wise from January 2025 to June 2025**

Title of paper	Name of the author/s	Name of journal	Impact Factor
Chitosan Nanocarriers: A Promising Approach For Glioblastoma Therapy	Poulami Sarkar*, Arindam Manna, Soumyadip Bera , Olivia Sen, Priya Das, Sreejan Manna*, et al.	Carbohydrate Polymers	10.7
Elucidating The Anti-Inflammatory Potential of Nanoscaled Polymeric-Albumin Blends of Garcinol: Optimization, In Silico, In Vitro, And In Vivo Studies	Shayeri Chatterjee Ganguly, Purna Chandra Pal	International Journal of Biological Macromolecules	7.7
Targeting Friend Leukemia Integration 1: A Promising Approach For Prevention And Treatment of Solid Tumors	Moumita Kundu, Pallab Kumar Maji, et al.	International Journal of Biological Macromolecules	7.7
Chemically Modified Hyaluronic Acid Derivatives As Ocular Drug Carriers: A Review	Olivia Sen, Sreejan Manna*, et al.	International Journal of Biological Macromolecules	7.7
Thermoresponsive Solid Lipid Nanoparticles And Its Potential For Cns Tumor Therapy	Shiuli Bera, Shayeri Chatterjee Ganguly, Priya Manna, Moumita Kundu*, et al.	International Journal of Pharmaceutics	5.3
Chemoinformatic modelling,inverse docking and molecular simulations-driven design for multilayered prioritization of novel leishmanicidal agents based on a 2-aminobenzimidazole scaffold.	Arpita Biswas et al.	Molecular Diversity	3.8
Silica Nanoparticles: A Promising Vehicle for Anti-Cancer Drugs Delivery	Kazi Julekha et al.	Aaps Pharmscitech	3.4

Exploring The Impact of Polysaccharide-Based Nanoemulsions In Drug Delivery	Ayon Dutta,et al.	Journal of Biomedical Materials Research Part B: Applied Biomaterials	3.2
Advance In Prostate Cancer Biomarker Discovery: Bridging Detection, Prognosis And Therapeutics	Shayeri Chatterjee Ganguly, Shiuli Bera & Moumita Kundu*, et al.	Discover Oncology	2.8
Alginate-Based Target Specific Bioadhesive Drug Delivery Systems: A Review	Sreejan Manna*, Nirmal Chandra Nath, Poulami Sarkar, Olivia Sen*, et al.	International Journal of Polymeric Materials and Polymeric Biomaterials	2.6
Replication Stress Response And Radioresistance In Lung Cancer: Mechanistic Insights And Advanced Therapeutic Approaches	Moumita Kundu, et al.	Current Problems in Cancer	2.5
Formulation of Morus Alba Extract Loaded Solid Lipid Nanoparticles: In Silico, Characterizations, And In Vitro Cytotoxicity Study	Saptarshi Samajdar et al.	Drug Development and Industrial Pharmacy	2.4
Amplifying Therapeutic Potential Through Optimization of Bioavailability of Poorly Soluble Flavonols Via Albumin-Based Nanoparticles	Shayeri Chatterjee Ganguly, Ritam Maity, Priya Manna, Avishek Sardar et al.	Drug Development and Industrial Pharmacy	2.4
Advancements In Biomaterials For Regenerative Medicine Through Tissue Engineering In Quest of Sustainability	Shayeri Chatterjee Ganguly, et al.	Regenerative Engineering and Translational Medicine	2.2
In Silico Identification of Potential Inhibitors For Dengue Virus Ns5 Methyltransferase: Molecular Docking, Dynamics, Dft, And Adme Analysis	Purna Chandra Pal, et al.	Chemistryselect	1.9
Design, Synthesis, And Pharmacological Evaluation of Novel Isatin Scaffolds As Potent Anti-Inflammatory And Antibacterial Agents	Prasenjit Mondal*, Sreejan Manna, Paramita Ganguly, Zainab Irfan, et al.	Chemistryselect	1.9
Antidiabetic Activities of Aerial Part of Asparagus Racemosus Willd. Extract: An In Vitro, In Vivo, And In Silico Approach	Priya Das, et al.	Zeitschrift Für Naturforschung C	1.8
Enhancing Vaginal Drug Delivery: The Nanoemulsion Gel Strategy	Ayon Dutta, et al.	Zeitschrift Fur Naturforschung Section C-A Journal of Biosciences	1.8

Advanced Uplc-Photo Diode Array Method For Precise Quantification of Sotagliflozin In Bulk And Commercial Formulations	Bramhajit Chatterjee, Prasenjit Mondal, et al.	Oriental Journal of Chemistry	0.3
Elucidating The Anti Inflammatory Potential of Bio Active Hydrogel From Carica Papaya Leaf Extracts Using Combination of In Silico And In Vitro Methods	Saptarshi Samajdar, Debmalya Biswas, Ritabrata Das, et al.	International Journal of Ayurvedic Medicine	0.1


Faculty Achievements



Ms.Piyali Khamkat, Associate Professor, Department of Pharmaceutical Technology, received the 1st prize “Ideas for Life Science” under “To adopt a healthy lifestyle” from **Hon.Chief Minister of Delhi, Smt. Rekha Gupta, Manjindar Singh Sirsha, and Minister Shri Bhupender Yadav.**



From the Department of Pharmaceutical Technology, Dr. Sreejan Manna, Dr. Saptarshi Samajdar, Ms. Piyali Khamkat were awarded with appreciation from Honourable Vice Chancellor Prof. (Dr) Sankar Gangopadhyay for the highest number of paper publications among 650+ Brainware University faculties.



Dr. Ramesh Kumari Dasgupta, Professor, Department of Pharmaceutical Technology, has published a book entitled “A Text Book of Advanced Analytical Techniques”.



The faculties of the **Department of Pharmaceutical Sciences** won the **Runner-up trophy** in the university-organised sports event “**ULLAS-2025**” in the **Tug-of-War** for the male category.



Dr. Kausik Bhar, Associate Professor in the Department of Pharmaceutical Technology, was awarded the first prize as the most popular reader by the departmental library.

Student Achievements



Manami Sardar, MPharm student from Pharmaceutical Chemistry, Department of Pharmaceutical Technology, has secured

- **1st Prize** at Jadavpur University's International Conference on Modern Medicine and Rational Use of Medicine and
- **3rd Prize** at the 2nd International Conference on Innovations in Sustainable Drug Discovery & Development for **Poster Presentation**



Mr. Agnik Banerjee and Ms. Sanjana Singha, 1st-year B.Pharm students, Department of Pharmaceutical Technology, for securing the 1st Prize in Poster Presentation in a conference organized by Dr. B.C Roy College of Pharmacy & Allied Sciences.

GPAT and NIPER-2024 Rankers



Prottyush Goswami



Srijita Chatterjee



Tuhin Subhra Jana

Sl. No.	Student Name	Student Code	AIR	Entrance Qualified	Batch
1	Prottyush Goswami	BWU/BPH/021/043	1480	GPAT	2021
2	Srijita Chatterjee	BWU/BPH/021/094	3902	NIPER JEE	2021
3	Tuhin Subhra Jana	BWU/BPH/022/008	382	GPAT	2022

Departmental Best Practices

28.02.2025- Inauguration of Drug Information Centre (DIC)



On February 28th 2025, the Department of Pharmaceutical Technology, Brainware University, inaugurated the Drug Information Centre (DIC). Honourable VC Prof. Sankar Gangopadhyay led the event, joined by Registrar Mohua Paul and Dean Prof. Anand Kumar Srivastav. The DIC aims to provide reliable medication information and enhance patient care.

7.06.2025 – Teachers Talk Season 1 Concludes: Celebrating a Journey of Academic Exchange and Inspiration



On June 7th 2025, the Department of Pharmaceutical Technology, Brainware University, successfully concluded the **Teachers Talk Season -01** with the concluding session by **Dr. Prasenjit Mondal**, Head of the Department, with an **enriching Teacher's Talk session**, creating a vibrant and dynamic academic atmosphere.

17.01.2025 – Honouring Academic Brilliance: HOD's Appreciation Award for Publication Excellence – Winter Session 2025



On January 17th 2025, Dr. Prasenjit Mondal, Head of the Department, Department of Pharmaceutical Technology, felicitated faculty members with medals and mementos during the Winter Session Appreciation Awards in recognition of their outstanding contributions to research and scholarly publications.

15.07.2025 – Honoring Academic Brilliance: HOD's Appreciation Award for Publication Excellence – Summer Session 2025



Dr. Prasenjit Mondal, Head of the Department, Department of Pharmaceutical Technology, honored the department's faculty with medals and mementos during the Summer Session Appreciation Awards for their outstanding contributions to research and publications.

Special Achievements	Faculty Name
Highest Number of Publication	Dr. Sreejan Manna
Highest Publication as a first author	Dr. Shayeri Chatterjee Ganguly
Publication with highest Impact factor	Ms. Poulami Sarkar
Highest publication with impact factor	Ms. Olivia Sen



Dr. Sreejan Manna
(Associate Professor)



Dr. Shayeri Chatterjee Ganguly
(Associate Professor)



Ms. Olivia Sen
(Assistant Professor)





Ms. Poulami Sarkar
(Assistant Professor)

Felicitations for PhD-awarded Faculties



During the HOD's appreciation award ceremony, the Head of the Department, **Department of Pharmaceutical Technology, Prof. (Dr). Prasenjit Mondal** felicitated the newly Ph.D awarded faculties, **Dr. Sreejan Manna, Dr. Shayeri Chatterjee Ganguly, and Dr. Priya Das.**

Driving Discovery: Launch of Departmental Research Consultancy Services for Collaborative Innovation


	BRAINWARE UNIVERSITY	 ব্রেনওয়ার বিশ্ববিদ্যালয়
Department of Pharmaceutical Technology PRECISION RESEARCH CONSULTING SERVICES		
Sl. No.	Services	Price in INR (with GST)
1	Qualitative and Quantitative Phytochemical analysis by HPTLC Documentation System	1770/Sample *(Extracts and conditions of TLC need to be provided)
2	Antioxidant Assay (DPPH Assay and Hydrogen Peroxide Assay)	1180/Sample#
3	Antidiabetic Assay (α -Amylase assay)	2360/Sample#
4	Anti-inflammatory Assay (BSA and Egg albumin assay)	1180/Sample#
5	Anti Microbial Assay (For selected Bacteria [<i>E.coli</i> , <i>B.subtilis</i> , <i>B.cereus</i> , <i>P.aureginosa</i> , <i>S.typhi</i> , <i>S.aureus</i>] and Fungi[<i>C.albicans</i> , <i>A.niger</i>])	1180/Microbe/Sample#
6	Anthelmintic Assay	1770/Sample#
7	Proteolytic Assay	1180/Sample#
8	Determination of Particle Size upto μ m range (Quasmo Microscope)	354/Sample#
9	Stability studies of formulations as per ICH Guidelines (Long term and Accelerated)	2360/month/Sample#
10	Extraction of herbal products using Microwave assisted extraction and Ultrasonic extraction with phytochemical screening	590/Extracts (MAE) 354/Extracts(USE)
11	Tablet Punching with evaluation (Thickness, Hardness, Friability, Weight Variation,Disintegration)	590/50 Tablets *(Drug and Excipients to be provided by the client)
12	Tablet Punching with evaluation (Thickness, Hardness, Friability, Weight Variation, Dissolution, Disintegration, Drug Content)	1770/50 Tablets *(Drug and Excipients to be provided by the client)
13	QSAR Model Development	590 per model
14	Molecular Docking, ADME, Toxicity Prediction	1180/5 compound *(PDB ID, Compounds in .cdx form needed to be provided)
15	Network Pharmacology	1180/10 compound (SMILES code needs to be provided)
16	Method Development as per ICH guidelines (HPLC and UV)	23600/sample *(API & marketed formulation need to be provided)
17	Method Development as per ICH guidelines (HPLC and UV) with Forced degradation studies	35400/sample *(API need to be provided)
18	Isolation of Pure natural products for provided extracts.	23600/sample#
19	Evaluation of crude drugs (Total Phenolics, Total Alkaloid, Total Flavonoids, Total Aldehydes, Ash value, Extractive value, Morphological and Microscopic Studies)	1180/Sample#
20	Synthesis of derivatives by microwave synthesizer	2360/sample *(Scheme to be provided) 5900/sample *(with Scheme)
We also invites students/Scholars for short term projects upto 30 days		Pricing as per plan to be provided by the student/scholar
#Solubility profile of the samples are need to be provided.		

The Department of Pharmaceutical Technology has launched its Precision Research Consulting Services, offering over 20 specialized analytical, formulation, and bioassay services to support collaborative innovation in academia and industry.

Starting from 1st Semester 2025 – Learning by Doing: Launch of Project-Based Learning (PBL) from First Semester Onward

Department of Pharmaceutical Technology
BRAINWARE UNIVERSITY
ব্রেনওয়ার বিশ্ববিদ্যালয়

**INTRODUCES PROJECT-BASED LEARNING (PBL) FOR
B.PHARM & M.PHARM STUDENTS**
"Shaping Future Pharmacists through
Innovation, Inquiry & Impact"




Alongside the regular
B.Pharm and M.Pharm
curriculum

What is Project-Based Learning (PBL)?

Project-Based Learning is a student-centered approach that enables learners to explore, investigate, and solve real-world problems while applying their academic knowledge. It complements classroom teaching and builds practical skills crucial for pharmacy professionals.

Why PBL from the beginning of the programme? PBL + Curriculum = NEP 2020 in Action!
Starting early help students for:



Build Portfolio
Create a strong portfolio for future opportunities.

Foster Teamwork
Promote effective teamwork and communication.

Strengthen Skills
Enhance research and analytical abilities.

Develop Curiosity
Cultivate a curious and creative mindset.

Connect Theory
Integrate theoretical knowledge with practical application.

Contact Us:
Department of Pharmaceutical Technology
Brainware University, Kolkata
www.brainwareuniversity.ac.in
hod.pt@brainwareuniversity.ac.in

Starting from 1st Semester 2025 – Learning by Doing: The Department of Pharmaceutical Technology introduces Project-Based Learning (PBL) for B.Pharm and M.Pharm students, aligning with NEP 2020 to foster innovation, inquiry, and impact through hands-on, real-world problem solving.

MoU Highlights – Department of Pharmaceutical Technology

8.01.2025 – Fostering Partnerships: Signing of New Memoranda of Understanding (MOUs) to Expand Academic & Industry Collaboration



On January 17th 2025, the Department of Pharmaceutical Technology, Brainware University, proudly signed a Memorandum of Understanding (MoU) with Imethia Biosolutions, a modern laboratory specializing in clinical trials of drugs.



A Memorandum of Understanding (MoU) was inked between the **Department of Pharmaceutical Technology** and **Chromogen**, an ISO 9000:2015 certified incubator in Biotech Park, Kolkata, with a focus on "**Product Development**" using the findings of MPharm and PhD students.

Faculty Insights & Scholarly Reflections

FORMULATION AND EVALUATION OF HERBAL CREAM FOR SKIN CARE USING *ALOE VERA*

Soudip Das, Prahlad, Suman Kandar, Surajeet Manna, Md. Rakibuddin, Tanmay Samanta, Sanuar Hossain, Tuhinur Jaman Mallick, Habibulla Mollah, Tuhin Sinha, Souvik Pradhan, Bibek Das, Souvik Roy, Sujit Acharya, **Saptarshi Samajdar***

Department of Pharmaceutical Technology, Brainware University, 398, Ramkrishnapur Road, Barasat, Kolkata, 700125

*Corresponding Author's Mail: dss.pt@brainwareuniversity.ac.in

Introduction

The growing demand for herbal cosmetics is driven by new ingredients, financial incentives, and quality standards. *Aloe vera*, a preferred traditional medicine used for its therapeutic effects, is one of the most favorable traditional medicines. The gel from the aloe vera plant is rich in vitamins, enzymes and antioxidants and is reported to have soothing, anti-inflammatory, and moisturizing properties. It has been reported to treat acne, heal burns, and reduce scarring through the stimulation of collagen production. In this investigation, a topical skin care cream containing Aloe vera was prepared and evaluated for efficacy. [1,2].

Material and Method

Material

The *Aloe vera* leaf exudate powder was obtained from Bixa Botanicals, Bees Wax, Liquid Paraffin, Borax and Methyl Paraben were procured from Loba Chemie Ltd. All the works were performed using distilled water.

Preparation and evaluation of the herbal cream

White beeswax, liquid paraffin and powdered aloe to produce the oil phase, while water, borax, and methyl paraben made the aqueous phase. Both phases were mixed to develop a semisolid cream and lemon oil was added to the cream for fragrance. The formulations (F1 and F2) were examined for colour, odour, consistency, and condition. pH was recorded using a digital pH meter. Spreadability was determined by measuring the time taken for two slides to separate. Washability and skin irritation tests confirmed the formulations were safe. No phase separation occurred after storage. Stability testing involved incubating at $40 \pm 1^\circ\text{C}$ for 60 days, with observations recorded on day 0 and day 7 at $40 \pm 1^\circ\text{C}$, refrigerated at 4°C and in the dark cupboard. [3,4].

Result and Discussion

The F1 cream was a yellow cream, while F2 was yellow ochre. The lemon oil gave both a fresh scent with no rancidity. Both formulations had good consistency and were semisolid with plastic flow. They both had a near neutral pH (F1, 7.03; F2, 6.88). F1 had better spreadability (0.29 ± 0.06 g.cm/s) and better washability than F2 (Fig.1.). Both creams were stable, with no apparent phase separation throughout the storage time of 7 days, and demonstrated suitable moisturising and application properties. [5].




Fig. 1. Cream Formulations

Conclusion

F1 showed better stability, spreadability, and neutral pH, making it a safer, more effective herbal cream for cosmetic use.

References

1. Tiwari M, Dubey V, Lahiri A. Comparative study of various herbal cosmetics: A survey. Asian J Pharm Clin Res. 2020;13(10):31-4
2. Boudreau MD, Beland FA. An evaluation of the biological and toxicological properties of *Aloe barbadensis* (miller), *Aloe vera*. Journal of Environmental Science and Health Part C. 2006;24(1):103-54.
3. Dhase AS, Khadbadi SS, Saboo SS. Formulation and evaluation of vanishing herbal cream of crude drugs. Am J Ethnomed. 2014; 1:313-8.
4. Navindgikar NN, Kamalapurkar KA, Chavan PS. Formulation and evaluation of multipurpose herbal cream. International journal of current pharmaceutical research. 2020;12(3):25-30.
5. Dhyani A, Chander V, Singh N. Formulation and evaluation of multipurpose herbal cream. J. Drug Deliv. Ther. 2019;9(2):341-3.

INTEGRATING INDIGENOUS KNOWLEDGE INTO HEALTHCARE SYSTEMS AND EDUCATION

Isha Ghosh, Assistant Professor, Brainware University [ELS]
Arkaprava Ghosh, Assistant Professor, Brainware University [LAW]

Indigenous knowledge systems have historically been kept out of mainstream knowledge and practices. These communities have minimal representation in the global healthcare system and research. In recent scenarios, integrating Indigenous knowledge systems (IKS) in mainstream education and practices is a call for the hour to make the practices holistic, ecologically sustainable, and inclusive.

The limitations of a one-size-fits-all biomedical approach are highlighted by the persistence of health disparities among Indigenous people, including a greater incidence of chronic diseases and less access to care, despite technological breakthroughs. Frameworks with a cultural foundation, like Te Whare Tapa Whā in New Zealand and the Inuit Qaujimajatuqangit (IQ) model in Canada, show how incorporating Indigenous knowledge with traditional medical treatment enhances patient outcomes, trust, and community resilience (Tyagi, 2024; Harfield et al., 2022).

Indigenous knowledge places a significant emphasis on environmental harmony, prevention, and holistic well-being—aspects that are often overlooked in modern and contemporary treatment. For example, in Navajo and Māori tribes, traditional healing methods, including herbal medicine and spiritual ceremonies have been successful in controlling maternal health issues and chronic illnesses like diabetes (Tyagi, 2024; Brand et al., 2023). In addition to protecting cultural identity, these practices promote self-determination by enabling communities to take the lead in health programs. Indigenous knowledge-based curriculum in education gives aspiring medical professionals cultural competency and humility. Students' comprehension of ecological interdependence and ethical care is improved by programs that incorporate Indigenous viewpoints, such as Australia's planetary health education (Brand et al., 2023). Indigenous health lectures at

medical schools have been shown to significantly improve students' understanding and empathy over time, which is very important for lowering bias and enhancing patient relations (PMC, 2023). Institutional and policy support are essential. Systemic racism in Canadian healthcare is brought to light in the 2020 Report of Plain Sight, which promotes frameworks giving Indigenous leadership and intellectual property rights top priority. Functional, organisational, and normative alignment are necessary for successful integration; they include staff development that is culturally competent and community-led quality improvement (Harfield et al., 2022).

Thus, Indigenous knowledge fills in the sustainability and equality gaps that cannot be filled by cutting-edge science alone. Education and healthcare systems can be developed to be inclusive, efficient, and just by valuing different epistemologies.

References

1. Brand, G., et al. (2023). *Embedding Indigenous knowledge in planetary health education. International Journal of Special Education.*
2. Harfield, S., et al. (2022). *Integrating Indigenous healing practices within collaborative care models. BMJ Open.*
3. PMC. (2023). *Identifying methods to integrate Indigenous knowledge into education. PubMed Central.*
4. Tyagi, R. (2024). *The role of Indigenous knowledge in sustainable health practices. IHRDI Journal of Sustainable Development.*

A TRANSFORMATIVE TALE FROM PLACEMENT PANIC TO PROFESSIONAL PERFORMANCES

Mrs. Debolina Saha Chowdhury, Soft Skill Trainer, Training & Placement, Brainware University

“The coalesce of thoughts and actions brings an insight into constructive chronicles.” This materialistic world welcomes us all to enjoy both with freedom and fear. A fanatic individual will always find a fervour to passionately accomplish a task. This writing will illuminate the path of confidence and will eventually enlighten the readers with gleaming glimpse of master stroke.

From an outpouring heart of diligence, arises the fondness of fruition. Though an individual might be engulfed into various doubtful processes of execution, he/she in the fullness of time will be able to overcome the adversities in life. Living with facts and not in fantasy creates myriad exposures to one and all who cherishes to sign an ambitious accord with life. The transformative tale from placement panic to professional performances authenticates the stage with confidence, zeal, positive lookouts and bountiful valour.

Pharmacy and Allied Health Science programs are formulated with diversified curriculum structures, projects, internships, industrial training, clinical observations, industry visits and numerous placement drives. Students need to be adept with the sound knowledge of the subjects, skill developments, proactive participation in internships and industrial training for real life professional exposures along with hang-on experiences and build an eminent and empowered self-

image. As both Pharmaceutical and Allied Health Science professions provide an exemplary arena of drug developments, researches, diagnostics, therapeutic and rehabilitation services, it welcomes students with multitudinous career prospects and placement opportunities. It all lies in the sole hands of the students to hypothesize the efficiency of mastering the expertise of cracking job interview rounds. Communication Skills, technical sagacity, acquaintance with latest industry trends, a standardized and structured content of the resume all parallelly contribute to achieving a rewarding job.

The acknowledgement of self-power best acts like a victorious platform for candidates' exercise of duties within a formal occupational framework and gainful pursuits. Best utilization of educational resources and commitment into a workforce promote integration into the formal alignment of professional activities, eventually amplifying the visibility of candidates to stimulate interests and enthusiasm towards a job.

Herbal Garden Distinctive Activities

Department of Pharmaceutical Technology, Brainware University

Coordinator: Ms. Ananya Bhowmick

The Department of Pharmaceutical Technology initiated a year-long *Herbal Garden Distinctive Activity* (August 2024 – April 2025) for the D.Pharm 2024 batch as part of its practice-based learning approach. The initiative aimed to strengthen pharmacognostic skills, environmental stewardship, and the integration of traditional knowledge into modern pharmacy education.

Over 60 medicinal plants, such as **Tulsi, Amla, Arjuna, Aloe vera, Turmeric, Ginger, Pudina, and Kalmegh**, were cultivated and maintained by students. Each student/group was assigned specific plants, taking full responsibility for their care, identification, and documentation. Activities included organic fertilization, eco-friendly pest control, observation of growth patterns, and weekly records.

This experiential learning program bridged theory and practice, aligning with NAAC's student-centric and green campus initiatives. It enhanced knowledge in pharmacognosy, sustainable practices, teamwork, and professional skills, while also promoting traditional healing systems like Ayurveda and Unani.

Students reported increased environmental awareness, hands-on skills, and appreciation for herbal medicine. The activity not only enriched the green campus but also reinforced Brainware University's commitment to holistic, value-based pharmaceutical education.



Drug Information Bulletin

Drug Name	Tafamidis	Letermovir	Fexuprazan	Edoxaban
Indication	Treats cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults.	Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).	Treatment of erosive esophagitis.	Stroke prophylaxis with atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolus (PE).
Contraindications	Liver problems; pregnancy or planning to become pregnant; breastfeeding or planning to breastfeed.	Pimozide, ergot alkaloids, pitavastatin, or simvastatin (when co-administered with cyclosporine).	Hypersensitivity to the product or its components; use with atazanavir, nelfinavir, or rilpivirine; pregnant and lactating women; congenital conditions for lactose.	Active pathological bleeding.
Missed Dose	Skip the missed dose and take the next dose at the regularly scheduled time. Do not take two doses at the same time.	N/A	N/A	N/A
Side Effects	N/A	Nausea, vomiting, diarrhea, and peripheral edema.	Dyspepsia, headache, back pain.	Abnormal liver function tests, rash, anemia, interstitial lung disease, and major bleeding.
Drug Interactions	Methotrexate, rosuvastatin, or imatinib.	Cyclosporine, pitavastatin, and simvastatin.	Atazanavir and nelfinavir; clarithromycin and amoxicillin.	Defibrotide, aspirin, apixaban, ritonavir, and amiodarone.
Food-Drug Interactions	Can be taken with or without food.	Avoid St. John's Wort.	No food interactions reported.	Garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
Storage	N/A	N/A	Should be stored at a temperature not exceeding 30°C.	N/A

This Drug Information Bulletin was compiled by **Ms. Teasha Chakraborty, DIC (Drug Information Centre) In-Charge, Department of Pharmaceutical Technology, Brainware University**, as part of the department's initiative to enhance knowledge sharing and keep students and faculty updated on recent pharmacological developments.

Banned Antibiotic/Antibiotic Combination (Selected list) *

No.	Antibiotic (FDC)	Official Reason / Summary of Rationale
1	Azithromycin + Cefixime	Considered irrational / lacked therapeutic justification; risk of inappropriate spectrum & AMR; safety concerns.
2	Amoxicillin + Dicloxacillin	Duplicate/overlapping beta-lactam activity; no added benefit, thus irrational; AMR/safety concern.
3	Azithromycin + Levofloxacin	Combination of two broad-spectrum agents without justification → promotes resistance & safety risk.
4	Cefixime + Linezolid	Unjustified mix of cephalosporin + oxazolidinone (reserve antibiotic); inappropriate use and resistance risk.
5	Amoxicillin + Cefixime + Potassium clavulanate	Multiple beta-lactams + inhibitor in one pill — therapeutically redundant/irrational; safety/efficacy not established.
6	Ofloxacin + Nitazoxanide	Combination of fluoroquinolone + antiprotozoal without evidence for combined use; AMR & safety concerns.
7	Cefpodoxime + Levofloxacin	Two broad-spectrum antibiotics together — irrational prescribing; resistance risk.
8	Levofloxacin + Ornidazole + Alpha-Tocopherol acetate	Unwarranted combination (antibacterial + antiprotozoal + vitamin) — no clinical justification.
9	Nimorazole + Ofloxacin	Nitroimidazole + fluoroquinolone mixed without proven benefit — irrational; AMR risk.
10	Azithromycin + Ofloxacin	Two broad-spectrum antibiotics combined — no added therapeutic gain; resistance risk.
11	Amoxicillin + Tinidazole	Beta-lactam + nitroimidazole combination often marketed for “enteric/abdominal” syndromes but lacked evidence for routine use as FDC; irrational.
12	Doxycycline + Serratiopeptidase	Antibiotic + proteolytic enzyme — no robust therapeutic rationale; safety/labeling concerns.
13	Cefixime + Levofloxacin	Dual broad-spectrum use — irrational; AMR risk.
14	Ofloxacin + Metronidazole + Zinc acetate	Antibiotic + antiprotozoal + mineral — no evidence for combined fixed use; irrational.
15	Diphenoxylate + Atropine + Furazolidone	Antidiarrheal + antimicrobial (furazolidone) — safety & irrationality concerns (furazolidone toxicities).

16	Ciprofloxacin + Phenazopyridine	Fluoroquinolone + urinary analgesic — unjustified FDC; safety & antimicrobial stewardship issues.
17	Amoxycillin + Dicloxacillin + Serratiaopeptidase	Multiple beta-lactams + enzyme — redundant and irrational; safety/efficacy not supported.
18	Azithromycin + Cefpodoxime	Two broad-spectrum antibiotics together — irrational; resistance risk.
19	Metronidazole + Norfloxacin	Nitroimidazole + fluoroquinolone FDC — no compelling rationale; AMR/safety.
20	Metronidazole + Tetracycline	Two antibiotics combined without evidence for benefit as FDC — irrational; resistance risk.

**Sources for the table*

- **Primary:** Central Drugs Standard Control Organization (CDSCO) “List of Banned Drugs” (gazette notifications / updated banned drugs PDF).
- **Secondary/explanatory sources (rationale/impact / enforcement):** peer-reviewed reviews on India’s antimicrobial FDC bans and their rationale (public-health reasons: lack of evidence/therapeutic justification, safety, and risk of accelerating antimicrobial resistance).

List of Spurious Drugs

List of Drugs, declared as Spurious for the Month of June-2025 As part of the continuous regulatory surveillance, drugs samples are picked from sales/distribution point, analysed and list of spurious drugs are displayed on CDSCO portal on monthly basis. in the market.

S.No.	Name of Drugs/medical device/cosmetics	Batch No.	Date of Manufacture	Date of Expiry	Manufactured By	Reason for failure
1.	Cefixime Tablets IP (TAXIM-O 200 TABLETS)	24460967	Jul-2024	Jun-2026	Under Investigation	Identification and Assay of Cefixime Trihydrate
2.	Ointment of Heparin Sodium and Benzyl Nicotinate (THROMBOPHOB)	I404138	Aug-2024	Jul-2027	Under Investigation	Identification and Assay of Heparin Sodium
3.	Rosuvastatin and Fenofibrate Tablets IP	SIF2676A	12-2024	05-2027	Under Investigation	Description and Assay of Fenofibrate
4.	Rosuvastatin and Fenofibrate Tablets IP	SIF2736A	12-2024	05-2027	Under Investigation	Assay of Fenofibrate

Spurious Drugs: A drug shall be deemed to be spurious;

- If it is manufactured under a name which belongs to another drug; or
- if it is an imitation of, or is a substitute for, another drug or resembles another drug in a manner likely to deceive or bears upon it or upon its label or container the name of another drug unless it is plainly and conspicuously marked so as to reveal its true character and its lack of identity with such other drug; or
- If the label or container bears the name of an individual or company purporting to be the manufacturer of the drug, which individual or company is fictitious or does not exist; or
- If it has been substituted wholly or in part by another drug or substance; or
- If it purports to be the product of a manufacturer of whom it is not truly a product.

(The term “Spurious Drug” has been defined under Section 17-B of the Drugs and Cosmetics Act, 1940).

CONVOCATION 2025



Celebrating Academic Triumph: Convocation 2025 marks a proud milestone for our graduating scholars as they step into a future of promise and possibilities.

UNIVERSITY ACHIEVEMENTS 2025



**Pride & Prestige: Brainware University Honoured with ZEE 24 Ghanta
“Education Excellence Award.”**



**Brainware University Receives “Time Now Business Excellence Awards
East 2025.”**



Prestigious Time Business Awards 2025 Conferred on **Brainware University**

Student's Artwork



Artwork by- Aranya Dutta Banik, BPharm, 3rd Year

Created & designed by the Departmental Editorial Team — Brainware Pharma Chronicles (e-ISSN No. 3049-2831)

Disclaimer: "This newsletter is intended for informational and educational purposes only. The Department and Editorial Team are not responsible for any errors, omissions, or consequences arising from its use. The opinions expressed are solely those of the authors and do not reflect the official position of the Department or the University".

